The Biden-Harris administration has introduced a proposed rule aimed at preventing pharmaceutical companies from circumventing Medicare drug price negotiations by adding new active ingredients to existing medications. The Centers for …
Tag:
Drug prices
-
-
Medicare Advantage Plans See Record Enrollment Amid Rising Healthcare Costs Medicare Advantage enrollment reached a record 25.3 million people in 2023, according to the Centers for Medicare & Medicaid Services …
-
Trump’s MFN Drug Pricing Policies: A Closer Look at the Impact and Challenges Trump’s MFN Drug Pricing Policies: A Closer Look at the Impact and Challenges Under President Donald Trump’s …
-
Innovations in Oncology: Highlights from the ASCO Annual Meeting The American Society of Clinical Oncology (ASCO) Annual Meeting remains the premier global event for cancer research, serving as the stage …
-
New Phase 3 Data Highlights Potential for ADC-Keytruda Combination in Lung Cancer Recent clinical data released ahead of the 2026 American Society of Clinical Oncology (ASCO) annual meeting signals a …
-
Capricor Therapeutics has initiated legal action against its distribution partners to ensure that patients with Duchenne muscular dystrophy (DMD) can access a potentially life-changing cell therapy. The lawsuit centers on …
-
Trump and Epstein Files: DOJ Releases Additional Documents Amidst Allegations The Justice Department recently released additional documents from the Jeffrey Epstein files, containing decades-ancient sexual assault allegations against President Donald …
-
Trump Receives More Credit Than Biden for Lowering Drug Prices WASHINGTON — Despite the Biden administration’s efforts to lower prescription drug costs, a new poll indicates that former President Trump …
-
Biotech VC Aids Epstein Associate’s Return to Industry A biotech investor with ties to convicted sex offender Jeffrey Epstein is making a comeback in the venture capital world, aided by …
-
FDA Reverses Course on Moderna Flu Vaccine, Scrutinizes Telehealth GLP-1s The Food and Drug Administration (FDA) is navigating a period of significant shifts, recently reversing its stance to review Moderna’s …
Newer Posts